ARPO - Aerpio Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9900
+0.0200 (+2.06%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.9700
Open0.9800
Bid0.9500 x 1000
Ask1.0300 x 1200
Day's Range0.9600 - 1.0200
52 Week Range0.8800 - 4.9500
Volume167,548
Avg. Volume564,733
Market Cap40.182M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks10 days ago

    Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock?

    Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Business Wire14 days ago

    Aerpio Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.

  • MarketWatchlast month

    Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment

    Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed to meet its primary endpoint of improvement over placebo. The stock was the biggest decliner listed on major U.S. exchanges, with volume reaching 5.5 million shares, or about 22 times the full-day average. Meanwhile, the company said the trial of its lead candidate AKB-9778 was found did to be safe and well tolerated and showed some encouraging in some secondary endpoints. "While we are disappointed in the primary endpoint results of this study, we are nevertheless encouraged by the fact that several other promising findings observed in our prior 3-month Phase 2a trial have been prospectively confirmed in this 1-year trial," said Chief Executive Stephen Hoffman. The company said it plans to provide an update on the status of AKB-9778 after a full analysis. The stock has now lost 37% over the past 3 months while the iShares Nasdaq Biotechology ETF has gained 16% and the S&P 500 has tacked on 11%.

  • Greater Cincinnati pharma firm’s stock plummets
    American City Business Journalslast month

    Greater Cincinnati pharma firm’s stock plummets

    Shares dropped more than 70 percent March 18 after the company disclosed the results of a clinical trial.

  • Business Wirelast month

    Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line results from the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration of AKB-9778 twice daily did not meet the study’s primary endpoint of the percentage of patients with an improvement of two or more steps in the study eye diabetic retinopathy severity score (DRSS) compared to placebo.

  • GuruFocus.comlast month

    Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Aerpio Pharmaceuticals Inc is a biopharmaceutical company. Warning! GuruFocus has detected 2 Warning Signs with IRMD. For the last quarter Aerpio Pharmaceuticals Inc reported a revenue of $0.00 million, compared with the revenue of $0.00 million during the same period a year ago.

  • Business Wirelast month

    Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy Expected in March 2019

  • Business Wire2 months ago

    Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that its fourth quarter and full year 2018 financial results will be released before the market opens on Tuesday, March 5, 2019. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EST to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.

  • Aerpio (ARPO) Jumps: Stock Rises 7.8%
    Zacks3 months ago

    Aerpio (ARPO) Jumps: Stock Rises 7.8%

    Aerpio (ARPO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Business Wire3 months ago

    Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). "We are pleased to announce completion of patient dosing in our 48-week Phase 2b trial, TIME-2b,” said Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio. AKB-9778 is our first-in-class, systemically-administered Tie2 activator in development for the treatment of diabetic retinopathy, as well as complications of diabetes and other ocular diseases.

  • Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever
    American City Business Journals5 months ago

    Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever

    The stock market soared Wednesday with the Dow Jones Industrial Average posting its fifth-biggest point gain ever.

  • GlobeNewswire5 months ago

    Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire5 months ago

    Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:00 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.

  • Business Wire5 months ago

    Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update

    TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track

  • Business Wire6 months ago

    Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that its third quarter 2018 financial results will be released before the market opens on Wednesday, November 7, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EST to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.

  • Business Wire6 months ago

    Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that the Company will present renal function data obtained from the TIME-2 Phase 2 clinical trial of AKB-9778 in diabetic retinopathy patients at the American Society of Nephrology (ASN) Kidney Week 2018, Oct. 23-28, in San Diego. “VE-PTP, an inhibitor of Tie2, is expressed in the kidney and may be upregulated in patients with diabetes,” said Kevin Peters, M.D., chief scientific officer of Aerpio Pharmaceuticals.

  • Business Wire7 months ago

    Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

    Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Monday, October 1, 2018 at 10:40 a.m.

  • Business Wire8 months ago

    Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC

    Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.

  • Benzinga8 months ago

    The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

    Here's a roundup of top developments in the biotech space over the last 24 hours.  Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...

  • Business Wire8 months ago

    Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update

    TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track; Data in Q2 2019

  • ACCESSWIRE8 months ago

    Aerpio Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern ...

  • Business Wire8 months ago

    Aerpio Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 14, 2018

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that its second quarter 2018 financial results will be released before the market opens on Tuesday, August 14, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.

  • Business Wire10 months ago

    Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock

    Aerpio Pharmaceuticals, Inc. (ARPO) (“Aerpio”) today announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announced today the pricing of the previously announced underwritten public offering of 11,688,000 shares of its common stock at a price to the public of $3.85 per share. Aerpio has also granted the underwriters a 30-day option to purchase up to an additional 1,753,200 shares of common stock to cover overallotments, if any.

  • Business Wire10 months ago

    Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

    Aerpio Pharmaceuticals, Inc. (ARPO) (“Aerpio”) today announced that it intends to sell, subject to market and other conditions, $40 million of its common stock in an underwritten public offering. Aerpio also intends to grant the underwriters a 30-day option to purchase an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. Aerpio also announced that its common stock has been approved for listing on the Nasdaq Capital Market, subject to the pricing of the public offering on the terms proposed.